Statements (133)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:Johnson_&_Johnson
gptkb:Abb_Vie |
| gptkbp:activities |
gptkb:Bruton_tyrosine_kinase_inhibitor
|
| gptkbp:approves |
gptkb:Waldenström's_macroglobulinemia
gptkb:healthcare_organization gptkb:2013 gptkb:Brazil gptkb:FDA gptkb:Japan gptkb:Politician gptkb:Singapore gptkb:Switzerland mantle cell lymphoma |
| gptkbp:class |
gptkb:Cloud_Computing_Service
targeted therapy antineoplastic agent |
| gptkbp:clinical_trial |
gptkb:Waldenström's_macroglobulinemia
gptkb:healthcare_organization ongoing combination therapy Phase 3 mantle cell lymphoma monotherapy NC T02477696 NC T01805924 NC T02141257 NC T02264574 NC T02004655 NC T02101853 NC T02343120 first-line treatment for CLL relapsed or refractory CLL treatment for MCL treatment for SLL treatment for WM treatment for chronic graft-versus-host disease treatment for marginal zone lymphoma |
| gptkbp:contraindication |
active bleeding disorders
severe hepatic impairment concomitant use with strong CY P3 A inhibitors concomitant use of strong CY P3 A inhibitors |
| gptkbp:developed_by |
gptkb:Abb_Vie
|
| gptkbp:discovered_by |
gptkb:Pharmacyclics
|
| gptkbp:dosage_form |
gptkb:beer
gptkb:tablet 140 mg capsule 280 mg capsule 420 mg capsule |
| gptkbp:effective_date |
2013-11-13
|
| gptkbp:excretion |
urine
feces |
| gptkbp:formulation |
gptkb:beer
gptkb:tablet ibrutinib 140 mg ibrutinib 280 mg ibrutinib 420 mg ibrutinib 560 mg ibrutinib 840 mg |
| gptkbp:has_ability |
140 mg
280 mg 420 mg |
| gptkbp:healthcare |
gptkb:battle
|
| https://www.w3.org/2000/01/rdf-schema#label |
Imbruvica
|
| gptkbp:indication |
B-cell malignancies
|
| gptkbp:ingredients |
gptkb:ibrutinib
C19 H24 N2 O2 S |
| gptkbp:interacts_with |
gptkb:warfarin
anticoagulants antiplatelet agents |
| gptkbp:invention |
2026
patented |
| gptkbp:is_atype_of |
L01 X X32
|
| gptkbp:is_used_for |
gptkb:Waldenström's_macroglobulinemia
gptkb:healthcare_organization mantle cell lymphoma treatment of certain types of cancer |
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:Abb_Vie
|
| gptkbp:marketed_as |
gptkb:legislation
gptkb:ibrutinib gptkb:Australia gptkb:United_States gptkb:Imbruvica gptkb:Native_American_tribe |
| gptkbp:metabolism |
CY P3 A4
|
| gptkbp:packaging |
blister packs
bottles of 30 capsules |
| gptkbp:pharmacokinetics |
bioavailability 100% (oral)
metabolized by CY P3 A4 bioavailability 100% after oral administration half-life 4-5 hours |
| gptkbp:population |
adults
pediatric patients |
| gptkbp:previous_name |
gptkb:battle
|
| gptkbp:price |
approximately $14,000 per month
|
| gptkbp:provides_information_on |
included in ASCO guidelines
included in NCCN guidelines |
| gptkbp:research_and_development |
ongoing studies for other cancers
|
| gptkbp:research_areas |
oncology
hematology immunology collaborated with academic institutions collaborated with hospitals |
| gptkbp:safety_features |
gptkb:2019
gptkb:2020 gptkb:2021 gptkb:2022 gptkb:2023 risk of bleeding risk of infections risk of cardiac arrhythmias risk of tumor lysis syndrome |
| gptkbp:scholarships |
available for education
available for financial assistance available for adherence support |
| gptkbp:side_effect |
gptkb:fandom
fatigue nausea hypertension bruising diarrhea rash thrombocytopenia neutropenia increased risk of infection arthralgia |
| gptkbp:storage |
store at room temperature
keep away from moisture |
| gptkbp:type_of |
936563-96-1
|
| gptkbp:type_of_care |
important for treatment efficacy
|
| gptkbp:year_created |
gptkb:2003
|